Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avelumab + bempegaldesleukin
- Development stage
- Unknown
- Lead developer
- Nektar Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Avelumab + bempegaldesleukin is an investigational combination regimen of avelumab, a human anti–PD-L1 monoclonal antibody immune checkpoint inhibitor, and bempegaldesleukin (NKTR-214), a PEGylated IL-2 cytokine prodrug that acts as a CD122-preferential IL-2 pathway agonist. The combination is designed to enhance antitumor immune responses by both blocking PD-L1–mediated immunosuppression (through avelumab) and preferentially activating and proliferating tumor-infiltrating CD8+ T cells and NK cells without expanding regulatory T cells (through bempegaldesleukin). This combination has been evaluated in clinical trials for recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) and metastatic castration-resistant prostate cancer (mCRPC)[1][6][8][2][7].
- Other names
- avelumab + NKTR-214
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on avelumab + bempegaldesleukin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avelumab + bempegaldesleukin.